Use of grf1 protein and cells expressing grf1 protein for screening molecules
CA 2418655 C · Owner: Wahl, Florence · Inventors: Wahl, Florence; Stutzmann, Jean-Marie; Ret, Gwenaelle
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns the use of whole or part of the GRF1 protein or of cells expressing whole or part of the GRF1 protein in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia Parkinson's disease or Alzheimer's disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 7, 2001 and granted December 13, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 7, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 7, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.